MA39942A - Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 - Google Patents

Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2

Info

Publication number
MA39942A
MA39942A MA039942A MA39942A MA39942A MA 39942 A MA39942 A MA 39942A MA 039942 A MA039942 A MA 039942A MA 39942 A MA39942 A MA 39942A MA 39942 A MA39942 A MA 39942A
Authority
MA
Morocco
Prior art keywords
radiotherapy
treatment
positive cancers
combination
immuno therapy
Prior art date
Application number
MA039942A
Other languages
English (en)
French (fr)
Inventor
Nicola Mason
Yvonne Paterson
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/268,436 external-priority patent/US20140234370A1/en
Priority claimed from PCT/US2015/017559 external-priority patent/WO2015130810A2/en
Priority claimed from US14/669,629 external-priority patent/US10016617B2/en
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MA39942A publication Critical patent/MA39942A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA039942A 2014-05-02 2015-04-02 Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2 MA39942A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14/268,436 US20140234370A1 (en) 2009-11-11 2014-05-02 Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors
US201462076411P 2014-11-06 2014-11-06
PCT/US2015/017559 WO2015130810A2 (en) 2014-02-25 2015-02-25 Compositions and methods for the treatment of her2/neu over-expressing tumors
US14/669,629 US10016617B2 (en) 2009-11-11 2015-03-26 Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers

Publications (1)

Publication Number Publication Date
MA39942A true MA39942A (fr) 2017-03-08

Family

ID=54359144

Family Applications (1)

Application Number Title Priority Date Filing Date
MA039942A MA39942A (fr) 2014-05-02 2015-04-02 Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2

Country Status (11)

Country Link
EP (1) EP3137107A4 (de)
JP (1) JP2017514904A (de)
KR (1) KR20170002552A (de)
CN (1) CN106794234A (de)
AU (1) AU2015253737A1 (de)
CA (1) CA2947677A1 (de)
IL (1) IL248704A0 (de)
MA (1) MA39942A (de)
MX (1) MX2016014367A (de)
SG (1) SG11201609135VA (de)
WO (1) WO2015167748A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP3332804A1 (de) 2011-03-11 2018-06-13 Advaxis, Inc. Adjuvanzien auf listerien-basis
EP2825195A4 (de) 2012-03-12 2015-10-07 Advaxis Inc Hemmung einer suppressorzellfunktion nach einer behandlung mit einem listerienimpfstoff
CN106456726A (zh) 2014-02-18 2017-02-22 阿德瓦希斯公司 生物标志物导向的多靶点免疫治疗
BR112016024352A2 (pt) 2014-04-24 2018-01-23 Advaxis, Inc. ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
KR20190034160A (ko) * 2016-06-03 2019-04-01 이투빅스 코포레이션 Her2/neu 가 관련되는 종양 백신화 및 면역요법을 위한 조성물 및 방법
EP3548623A4 (de) 2016-11-30 2020-11-25 Advaxis, Inc. Immunogene zusammensetzungen, die auf wiederkehrende krebsmutationen abzielen, und verfahren zur verwendung davon
EP3684912A4 (de) 2017-09-19 2021-04-14 Advaxis, Inc. Zusammensetzungen und verfahren zur lyophilisierung von bakterien- oder listerienstämmen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
AU2004281834A1 (en) * 2003-10-15 2005-04-28 Cerus Corporation Listeria-based EphA2 vaccines
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
JP5985397B2 (ja) * 2009-11-11 2016-09-06 アドバクシス インコーポレイテッド 組換えリステリア株およびそれを含む免疫原性組成物
WO2011100754A1 (en) * 2010-02-15 2011-08-18 The Trustees Of The University Of Pennsylvania Live listeria-based vaccines for central nervous system therapy
EP2576791B8 (de) * 2010-05-23 2016-12-21 Aduro BioTech, Inc. Verfahren und zusammensetzungen mit listeria zur hilfsbehandlung von krebs

Also Published As

Publication number Publication date
KR20170002552A (ko) 2017-01-06
SG11201609135VA (en) 2016-11-29
IL248704A0 (en) 2017-01-31
CN106794234A (zh) 2017-05-31
EP3137107A1 (de) 2017-03-08
JP2017514904A (ja) 2017-06-08
MX2016014367A (es) 2017-06-30
AU2015253737A1 (en) 2016-12-22
CA2947677A1 (en) 2015-11-05
WO2015167748A1 (en) 2015-11-05
EP3137107A4 (de) 2018-01-17

Similar Documents

Publication Publication Date Title
MA39942A (fr) Immunothérapie et radiothérapie combinées pour le traitement de cancers positifs à her-2
IL280707A (en) Diagnostic and therapeutic methods for treating breast cancer
IL261008A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
IL297418B1 (en) Combined immunotherapy and cytokine control therapy for cancer treatment
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
IL272740A (en) Combined immunotherapy and cytokine control therapy for cancer treatment
MX2019011148A (es) Metodos de tratamiento.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2016011114A (es) Composiciones y metodos para el tratamiento de tumores que sobreexpresan her2/neu.
GEP20217317B (en) Combination therapy for the treatment of cancer
MX2018001755A (es) Vacuna contra viruela para tratamiento del cancer.
MX2019003722A (es) Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan.
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
IL279591A (en) Cancer treatment methods using combination therapy
IL281845A (en) Combined treatment for cancer
IL281439A (en) Combined treatment for blood cancer
IL284162A (en) Integrated healing for cancer treatment
IL279277A (en) In vivo controlled combination therapy for treatment of cancer
IL276068A (en) iort device for radiotherapy treatment in cancer patients
EP4037761C0 (de) Vorrichtung zur strahlentherapiebehandlung von krebspatienten
IL275913A (en) Methods and combined treatment for cancer treatment
MX2021001288A (es) Vacunacion con microvesiculas derivadas de celulas tumorales para tratamiento de cancer.